Search
Poloxamer 188
go.drugbank.com/drugs/DB11333ApprovedThe use of P188 as a potential treatment in different pathological conditions, such as chronic microvascular diseases and skeletal muscle deficiencies, is under investigation [A27217]. … P188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217].
Categories: Compounds used in a research, industrial, or household setting, P-glycoprotein inhibitorsBirch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational(white birch), although hybrids of both species are used as well. … [L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme InhibitorsEslicarbazepine
go.drugbank.com/drugs/DB14575ApprovedEslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate].
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersNerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … Nerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsQuazepam
go.drugbank.com/drugs/DB01589ApprovedIllicitQuazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsMifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalAs a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. … Mifepristone is a progestational and glucocorticoid hormone antagonist.
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsNiflumic acid
go.drugbank.com/drugs/DB04552InvestigationalNiflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
Phenformin
go.drugbank.com/drugs/DB00914ApprovedWithdrawnA biguanide hypoglycemic agent with actions and uses similar to those of metformin. … Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesTibolone
go.drugbank.com/drugs/DB09070ApprovedInvestigationalTibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha [L1874]. … In June 2006, Organon Pharmaceuticals announced the receipt of a Not Approvable Letter from the U.S.
Roxatidine acetate
go.drugbank.com/drugs/DB08806InvestigationalRoxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.